J&J's Innovative Medicine Segment in Q4: Here's What to Watch

Key Takeaways JNJ posted 3.4% organic Innovative Medicine sales growth in first nine months of 2025 despite Stelara's LOE.JNJ expects Q4 growth from Darzalex, Tremfya and Erleada and strong uptake of newer drugs.JNJ faces pressure from Stelara biosimilars, weaker Imbruvica sales and Part D redesign effects.Johnson & Johnson (JNJ) , through its Innovative Medicine segment, commercializes multiple blockbuster therapies spanning a wide range of disease areas, such as neuroscience, cardiovascular and metabolic ...